Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CDA | P32320 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 3/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903970 | 0.83 | PYGM (0.49) | CDK1MAPTCDAPYGMSLC5A2 | |
| SCHEMBL5903974 | 0.83 | PYGM (0.49) | CDK1MAPTCDAPYGMSLC5A2 | |
| SCHEMBL17504390 | 0.78 | TK2 (0.42) | CDK1MAPTCDAPYGMSLC5A2 | |
| SCHEMBL28997350 | 0.77 | PDE4D (0.34) | CDASLC29A1 | |
| SCHEMBL17592611 | 0.75 | PDE4D (0.33) | CDASLC29A1 | |
| SCHEMBL7640658 | 0.73 | MAPT (0.47) | MAPTCDAPYGMSLC5A2SLC28A1 | |
| SCHEMBL635155 | 0.73 | MAPT (0.47) | MAPTCDAPYGMSLC5A2SLC28A1 | |
| SCHEMBL14829540 | 0.73 | LMNA (0.52) | — | |
| SCHEMBL5505144 | 0.73 | LMNA (0.52) | — | |
| SCHEMBL5580058 | 0.73 | LMNA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CDK1 1771/4885MAPT 4222/4885CDA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.